Kabazitaksel Teva

Cabazitaxel, the active ingredient in Kabazitaksel Teva, is a taxane presented as an injectable formulation for intravenous use. It is indicated for metastatic castration‑resistant prostate cancer in patients who have previously received docetaxel therapy.

GNH USA supplies Kabazitaksel Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. Our network ensures timely delivery and regulatory compliance for hospitals, pharmacies and cancer treatment facilities.

Cabazitaxel is a taxane chemotherapy used in the treatment of advanced prostate cancer.

- Metastatic castration‑resistant prostate cancer (mCRPC) after docetaxel: extends overall survival in patients with disease progression. - Hormone‑refractory prostate cancer: provides a chemotherapy option when hormonal therapies have failed. - Advanced prostate carcinoma: used when the disease progresses despite prior taxane therapy.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: marked reduction in neutrophil count. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: loss of hair on the scalp and body. - Nausea and vomiting: gastrointestinal upset. - Diarrhea: loose stools that may require supportive care. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring hospitalization. - Severe infections: opportunistic bacterial or fungal infections. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: significant elevation of liver enzymes. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Mucositis: painful inflammation of the mucous membranes.

When using Cabazitaxel, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: perform regular complete blood count tests to detect neutropenia. - Assess liver function: check hepatic enzymes before each cycle. - Evaluate for infection: postpone treatment if active infection is present. - Use caution in elderly patients: dose adjustments may be needed. - Avoid concurrent myelosuppressive agents: reduce risk of severe bone‑marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase cabazitaxel exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce cabazitaxel efficacy. - Other myelosuppressive agents: compound bone‑marrow toxicity. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): heightened bleeding risk. - CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism. - QT‑prolonging drugs (e.g., quinidine): monitor cardiac rhythm. - Electrolyte‑altering medications (e.g., diuretics): watch for arrhythmias.